Spreadsheet Data
Audit the saved peer set and the method inputs behind the blended fair value.
Review the saved peer set across price, scale, operating metrics, and raw valuation multiples.
| Peer | Price | Market Cap | Enterprise Value | Revenue | EBITDA | Net Income |
|---|
| P/E |
|---|
| P/S |
|---|
| EV/EBITDA |
|---|
BM BMRN BIOMARIN PHARMACEUTICAL INC FY ended Feb 19, 2026 | $64.67 | $12.52B | $10.76B | $3.22B | $567.70M | $348.90M | 35.93x | 3.89x | 18.47x |
ED EDIT Editas Medicine, Inc. FY ended Feb 27, 2026 | — | — | — | $40.52M | -$154.77M | -$160.06M | — | — | — |
SG SGMO SANGAMO THERAPEUTICS, INC FY ended Apr 20, 2026 | — | — | — | $39.55M | -$123.50M | -$122.93M | — | — | — |
NT NTLA Intellia Therapeutics, Inc. FY ended Feb 13, 2026 | — | — | — | $67.67M | -$410.71M | -$412.69M | — | — | — |
See which peer averages feed the weighted fair value and which methods are excluded.
| Method | Type | Avg. Multiple | Coverage | Implied Equity Value | Fair Value / Share | Status |
|---|---|---|---|---|---|---|
EV / EBITDA EVExcluded | Enterprise Multiple | 20.09x | 1/4 | -$4.59B | — | Target fundamentals do not produce a usable positive equity value. |
Price / Sales PSActive | Equity Multiple | 3.89x | 1/4 | $325.67M | $33.26 | Included in the active peer mix. |
Price / Earnings PEExcluded | Equity Multiple | 35.93x | 1/4 | -$8.65B | — | Target fundamentals do not produce a usable positive equity value. |
Open the saved peer table used to audit the fair value view.
| Peer | Price | Market Cap | Enterprise Value | Revenue | EBITDA | Net Income | P/E | P/S | EV/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
BM BMRN BIOMARIN PHARMACEUTICAL INC FY ended Feb 19, 2026 | $64.67 | $12.52B | $10.76B | $3.22B | $567.70M | $348.90M | 35.93x | 3.89x | 18.47x |
ED EDIT Editas Medicine, Inc. FY ended Feb 27, 2026 | — | — | — | $40.52M | -$154.77M | -$160.06M | — | — | — |
SG SGMO SANGAMO THERAPEUTICS, INC FY ended Apr 20, 2026 | — | — | — | $39.55M | -$123.50M | -$122.93M | — | — | — |
NT NTLA Intellia Therapeutics, Inc. FY ended Feb 13, 2026 | — | — | — | $67.67M | -$410.71M | -$412.69M | — | — | — |
Open the peer-average inputs behind the weighted result.
| Method | Type | Avg. Multiple | Coverage | Implied Equity Value | Fair Value / Share | Status |
|---|---|---|---|---|---|---|
EV / EBITDA EVExcluded | Enterprise Multiple | 20.09x | 1/4 | -$4.59B | — | Target fundamentals do not produce a usable positive equity value. |
Price / Sales PSActive | Equity Multiple | 3.89x | 1/4 | $325.67M | $33.26 | Included in the active peer mix. |
Price / Earnings PEExcluded | Equity Multiple | 35.93x | 1/4 | -$8.65B | — | Target fundamentals do not produce a usable positive equity value. |
